Clinical Trial: 20423

Trial Status: Open
Disease Type: Lung
Trial ID 20423
Sponsor ID eFT508-0011

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with NSCLC as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Principal Investigator
Timothy A. McCarthy, MD
5 Locations

Locations

Fairfax Office

Gainesville Office

Arlington Office

Alexandria Office

Loudoun Office

Learn More About This Trial

Other Relevant Trials
Trial ID 61186372NSC3004
Sponsor ID Paloma 3

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

1 Location
Trial ID 21318
Sponsor ID Roche Laboratories, Inc.

A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Principal Investigator
Timothy A. McCarthy, MD
5 Locations